MPMariela Laura Paz

Mariela Laura Paz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mariela Laura Paz has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • AChR-blocking antibodies and complement system dynamics: evaluating their interplay and clinical implications in myasthenia gravis

    by Florencia Aguirre, Mariano E. Justo, Lucía Cialdella, Mariela L. Paz

    Background Myasthenia gravis (MG) is an autoimmune disorder characterised by autoantibodies (abs) targeting proteins at the neuromuscular junction, primarily the acetylcholine receptor (AChR). While the role of AChR-binding abs is well-established, the pathogenicity and clinical relevance of AChR-blocking antibodies in MG, and their association with complement system, remain less understood. Aims This study aims to provide comprehensive insights into the prevalence and interplay of AChR-blocking antibodies and the complement system in an Argentinian MG cohort, investigating their relationships with disease activity. Methods We studied 75 MG patients with detectable AChR-binding abs, assessing the presence of AChR-blocking abs and complement components C3, C4, and C5a. We also examined clinical severity using the Activities of Daily Living and MG Composite scores. Correlation analyses were made to elucidate associations. Results AChR-blocking abs were detected in 49.3% of the patients. An inverse correlation was found between AChR-blocking abs titres and disease severity, with a higher titre associated with milder symptoms. Complement analysis revealed higher C4 levels in the AChR-blocking abs positive group, indicating reduced complement activation. Conclusion Our study provides valuable insights into the prevalence of AChR-blocking antibodies. Higher AChR-blocking abs titres were associated with less severe MG and reduced complement system activation, indicating a potential protective mechanism for those abs. These findings suggest that AChR-blocking abs could serve as a potential biomarker for a milder disease course and highlight the need for further research to understand their role in MG pathology, which will improve strategies for clinical management and diagnosis.


  • Open Access

    Amidinoquinoxaline N -oxides: synthesis and activity against anaerobic bacteria

    by Nadia Gruber, Liliana Fernández-Canigia, Natalia B. Kilimciler, Pierluigi Stipa, Juan A. Bisceglia, María B. García, Daniel H. Gonzalez Maglio, Mariela L. Paz, Liliana R. Orelli

    Amidinoquinoxaline N -oxides 1 show high antianaerobic activity, with CIM significantly lower than metronidazole in six cases, along with low cytotoxicity and promising ADME profiles. These nitrones represent a promising alternative to metronidazole.


  • C5a complement levels in clinical remission AQP4-IgG-positive NMO patients

    by Analisa Manin, Mariano E. Justo, Juliana Leoni, Mariela L. Paz, Andrés M. Villa

    Background Neuromyelitis Optica Spectrum Disorders (NMOSD) is an antibody-mediated disorder of the Central Nervous System where a leading role of the complement system has been demonstrated. Objective To measure the levels of complement factors C3, C4 and C5a in serum and plasma of clinical remission patients with AQP4-IgG + NMOSD. Methods Twelve patients with NMOSD AQP4 + according to 2015 criteria from a General Hospital in Buenos Aires, Argentina, were included in the study, and 19 age- and sex-matched healthy volunteers as a control group (HC). AQP4 antibodies were measured in serum by CBA analysis. Fresh blood samples were centrifuged to obtain serum and plasma. C3, C4, and AQP4 antibodies were measured in the serum, whereas C5a was measured in the plasma, which was obtained using Futhan (BD FUT-175®, BD Biosciences, San Jose, CA, USA). Results The complement factors, C3, C4, and C5a were measured in all samples. The mean concentration of C3 was 130.7 mg/dl (SD 16.1 mg/dl), and the mean concentration of C4 was 21.6 mg/dl (SD 4.8 mg/dl); both values were within the normal reference range (C3: 84–193 mg/dl; C4: 20–40 mg/dl) and were not significantly different (p > 0.05) from the mean levels in healthy controls (C3: 116.9 mg/dl; C4: 21.9 mg/dl). When analyzing the mean plasma level of C5a, we found a statistically significant difference (p = 0.0444) between the mean concentration of C5a in NMOSD patients (43.1 ng/ml; SD 48.7 ng/ml) and the HC group (17.7 ng/ml; SD 16.7 ng/ ml). Conclusions In conclusion, the present study demonstrates that plasma C5a may be interesting to investigate as a potential biomarker of disease activity in NMOSD, in a larger and prospective cohort.


  • Open Access

    Lipoteichoic Acid from Lacticaseibacillus rhamnosus GG Modulates Dendritic Cells and T Cells in the Gut

    by Adrián D. Friedrich, Juliana Leoni, Mariela L. Paz, Daniel H. González Maglio

    Lipoteichoic acid (LTA) from Gram-positive bacteria exerts different immune effects depending on the bacterial source from which it is isolated. Lacticaseibacillus rhamnosus GG LTA (LGG-LTA) oral administration reduces UVB-induced immunosuppression and skin tumor development in mice. In the present work, we evaluate the immunomodulatory effect exerted by LGG-LTA in dendritic cells (DC) and T cells, both in vitro and in the gut-associated lymphoid tissue (GALT). During cell culture, LTA-stimulated BMDC increased CD86 and MHC-II expression and secreted low levels of pro and anti-inflammatory cytokines. Moreover, LTA-treated BMDC increased T cell priming capacity, promoting the secretion of IL-17A. On the other hand, in orally LTA-treated mice, a decrease in mature DC (lamina propria and Peyer’s patches) was observed. Concomitantly, an increase in IL-12p35 and IFN-γ transcription was presented (lamina propria and Peyer’s Patches). Finally, an increase in the number of CD103+ DC was observed in Peyer’s patches. Together, our data demonstrate that LGG-LTA activates DC and T cells. Moreover, we show that a Th1-biased immune response is triggered in vivo after oral LTA administration. These effects justify the oral LTA activity previously observed.


  • Low Vitamin D Serum Levels in a Cohort of Myasthenia Gravis Patients in Argentina

    by Mariano E. Justo, Mayra Aldecoa, Eliana Cela, Juliana Leoni, Daniel H. González Maglio, Andrés M. Villa, Florencia Aguirre, Mariela L. Paz

    There are limited and controversial studies that address the role of vitamin D (vitD), a vitamin with immunomodulatory effects, in myasthenia gravis (MG), a neuromuscular autoimmune disease. We aimed to assess 25‐hydroxy vitamin D (25(OH)D) levels and to evaluate possible associations with the clinical severity and other biomarkers of the disease. Serum levels of 25(OH)D, anti‐acetylcholine receptor antibodies and complement factor C5a were measured in MG patients ( n = 66) and healthy volunteers (HV) ( n = 25). Participants were evaluated through questionnaires to determine vitD intake and sunlight exposure. Severity scores were registered for MG patients. We found an 89.4% of MG individuals with nonsufficient levels of vitD, in comparison with 68.0% in the group of HV (OR = 3.96; P = 0.024). In addition, there was an inverse correlation between 25(OH)D levels and one of the scores ( P = 0.037 r = −0.26, CI 95 = −0.49 to −0.0087). However, when we compared 25(OH)D median serum levels between MG patients and HV, no statistically significant differences have been found. This is the first report of vitD status in a cohort of Argentinean MG patients, where we found that patients are more likely to have nonsufficient levels of vitD compared to healthy people and that patients with more severe disease have lower levels of vitD.


  • Impaired lung redox metabolism and cardiac mitochondrial function aggravates myocardial infarction in a mice model of chronic exposure to urban air pollution

    by Timoteo Marchini, Natalia Magnani, Mariana Garcés, Kelly Jazmín, Mariela Paz, Lourdes Cáceres, Romina Lasagni Vitar, Valeria Calabró, Laura Caltana, Mario Contin, et al.

  • Bioenergetic profiling in the skin

    by Daniel H. González Maglio, Timoteo Marchini, Eliana M. Cela, Natalia Magnani, Juliana Leoni, Mariela L. Paz, Pablo Evelson

  • Open Access

    NADPH oxidase and mitochondria are relevant sources of superoxide anion in the oxinflammatory response of macrophages exposed to airborne particulate matter

    by Lourdes Cáceres, Mariela L. Paz, Mariana Garcés, Valeria Calabró, Natalia D. Magnani, Manuela Martinefski, Pamela V. Martino Adami, Laura Caltana, Deborah Tasat, Laura Morelli, et al.


  • Open Access

    Nueva prueba diagnóstica para autoanticuerpos en Miastenia Gravis basado en un sistema de micropartículas fluorescentes libre de células

    by Mariela Laura Paz, Paula Natalia Manuelli, Daniel Horacio González Maglio, Florencia Aguirre, Andrés Villa, Juliana Leoni, Francisco José Barrantes

    Introducción: Se ha desarrollado una novedosa prueba diagnóstica para la detección de autoanticuerpos en pacientes con miastenia gravis. Este nuevo método, libre de células, es relativamente simple y consume menos tiempo y materiales que el radioinmunoensayo estándar, método de referencia utilizado actualmente en la clínica. Materiales y métodos: La prueba consiste en el uso de micropartículas de poliestireno recubiertas con el receptor de acetilcolina (se probaron dos fuentes de receptor de diferente origen), marcación específica del receptor con ligandos fluorescentes de alta afinidad (α-bungarotoxina-AlexaFluor o anticuerpos anti-receptor policlonales provenientes de los sueros de pacientes diagnosticados con la enfermedad, seguidos de anticuerpos secundarios conjugados con fluorocromos), y detección por citometría de flujo. Resultados: Los valores de intensidad de fluorescencia media para los sueros positivos por la técnica de referencia versus un pool de sueros humanos normales: mostraron una diferencia estadísticamente significativa para los dos tipos de micropartículas sensibilizadas utilizadas. Conclusión: Las dos estrategias diferentes evaluadas fueron exitosas para la detección de autoanticuerpos en el suero de pacientes con miastenia gravis. Adicionalmente esta prueba tiene el potencial para distinguir entre las distintas formas de los anticuerpos anti-receptor de acetilcolina, y los resultados podrían correlacionarse con la severidad de la miastenia gravis, pudiendo resultar un elemento predictivo de gran utilidad en el seguimiento de la evolución clínica de la enfermedad.